Board Meeting Details

The Board of Directors meeting was held on Thursday, November 12, 2026, commencing at 04:00 PM and concluding at 05:15 PM. The meeting approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026, and took note of the Limited Review Reports thereon.

Financial Results - Standalone (Rs. in Lakhs)

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹1,611.62
  • Other Income: ₹9.64
  • Total Revenue: ₹1,621.26
  • Total Expenses: ₹1,643.72
  • Loss Before Tax: ₹(22.46)
  • Tax Expenses: ₹(6.25) [Current Tax: ₹(6.25)]
  • Loss for the Period: ₹(28.71)
  • Basic EPS: ₹(0.01) [Not Annualized]
  • Diluted EPS: ₹(0.01) [Not Annualized]

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹2,789.13
  • Other Income: ₹9.67
  • Total Revenue: ₹2,798.80
  • Total Expenses: ₹2,790.96
  • Profit Before Tax: ₹7.84
  • Tax Expenses: ₹2.18 [Current Tax: ₹2.18]
  • Profit for the Period: ₹5.66
  • Basic EPS: ₹0.00 [Not Annualized]
  • Diluted EPS: ₹0.00 [Not Annualized]

Comparative Figures - Standalone:

  • Q2 FY26 (30.09.2025): Revenue ₹2,066.76, Profit ₹54.28, EPS ₹0.02
  • H1 FY26 (30.09.2025): Revenue ₹3,788.75, Profit ₹110.32, EPS ₹0.03
  • FY26 (31.03.2026): Revenue ₹7,603.44, Profit ₹198.77, EPS ₹0.06

Financial Results - Consolidated (Rs. in Lakhs)

Includes results of 3 subsidiaries: Polo Queen Capital Limited, Polo Queen Pharma Trade Industry Limited, and Polo Queen Solutions Limited.

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹1,611.62
  • Other Income: ₹40.85
  • Total Revenue: ₹1,652.47
  • Total Expenses: ₹1,643.98
  • Profit Before Tax: ₹8.49
  • Tax Expenses: ₹(0.83) [Current Tax: ₹(0.83)]
  • Profit for the Period: ₹9.32
  • Basic EPS: ₹0.00 [Not Annualized]
  • Diluted EPS: ₹0.00 [Not Annualized]

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹2,789.13
  • Other Income: ₹70.12
  • Total Revenue: ₹2,859.25
  • Total Expenses: ₹2,791.72
  • Profit Before Tax: ₹67.53
  • Tax Expenses: ₹15.07 [Current Tax: ₹15.07]
  • Profit for the Period: ₹52.46
  • Basic EPS: ₹0.02 [Not Annualized]
  • Diluted EPS: ₹0.02 [Not Annualized]

Comparative Figures - Consolidated:

  • Q2 FY26 (30.09.2025): Revenue ₹2,094.51, Profit ₹73.13, EPS ₹0.02
  • H1 FY26 (30.09.2025): Revenue ₹3,837.45, Profit ₹144.79, EPS ₹0.04
  • FY26 (31.03.2026): Revenue ₹7,688.60, Profit ₹256.96, EPS ₹0.08

Subsidiary Financials (Quarter Ended September 30, 2026)

  • Polo Queen Capital Limited: Assets ₹1,114.17 lakhs, Revenue ₹31.20 lakhs, Net Profit ₹25.95 lakhs
  • Polo Queen Pharma Trade Industry Limited: Assets ₹5.37 lakhs, Revenue ₹0.29 lakhs, Net Profit ₹0.29 lakhs
  • Polo Queen Solutions Limited: Assets ₹5.40 lakhs, Revenue ₹0.29 lakhs, Net Profit ₹0.29 lakhs

Capital Structure

  • Paid-up Equity Share Capital: ₹6,715.00 lakhs (Face Value ₹2 per share)
  • Standalone Reserves (previous year): ₹9,963.25 lakhs
  • Consolidated Reserves (previous year): ₹10,282.29 lakhs

Assets and Liabilities (Half Year Ended September 30, 2026)

Standalone:

  • Total Assets: ₹21,554.76 lakhs (Previous: ₹21,937.55 lakhs)
  • Non-current Assets: ₹19,807.63 lakhs
  • Current Assets: ₹1,747.13 lakhs
  • Total Equity: ₹19,023.39 lakhs
  • Non-current Liabilities: ₹747.97 lakhs
  • Current Liabilities: ₹1,783.40 lakhs

Consolidated:

  • Total Assets: ₹21,936.35 lakhs (Previous: ₹22,280.27 lakhs)
  • Total Equity: ₹19,389.22 lakhs
  • Total Liabilities: ₹2,547.13 lakhs

Segment Performance (Consolidated)

The company operates in four segments:

Quarter Ended September 30, 2026:

1. Trading: Revenue ₹1,621.26 lakhs, Segment Profit ₹15.16 lakhs

2. Non-Banking Financial Business: Revenue ₹31.21 lakhs, Segment Profit ₹30.47 lakhs

3. Pharma: Revenue ₹0.00 lakhs, Segment Profit ₹0.24 lakhs

4. ITITES: Revenue ₹0.00 lakhs, Segment Profit ₹0.24 lakhs

Half Year Ended September 30, 2026:

1. Trading: Revenue ₹2,798.80 lakhs, Segment Profit ₹84.33 lakhs

2. Non-Banking Financial Business: Revenue ₹60.45 lakhs, Segment Profit ₹59.21 lakhs

3. Pharma: Revenue ₹0.00 lakhs, Segment Profit ₹0.24 lakhs

4. ITITES: Revenue ₹0.00 lakhs, Segment Profit ₹0.24 lakhs

Auditor Review

N.K. Jalan & Co., Chartered Accountants, issued limited review reports for both standalone and consolidated financial results, stating that nothing has come to their attention that causes them to believe that the statements contain any material misstatement.

Additional Information

  • No exceptional items reported for any period
  • No non-controlling interest in any reporting period
  • Previous period figures have been regrouped where necessary
  • The financial results are in accordance with the accounting policies followed by the company